Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.23.3
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 907 $ 194 $ 5,149 $ 2,153
Research and development – licenses acquired 0 0 4,230 0
General and administrative 1,161 469 3,042 1,978
Loss from operations (2,068) (663) (12,421) (4,131)
Other income (expense):        
Interest income 9 1 104 4
Financing costs – warrant liabilities 0 0 (332) 0
Change in fair value of warrant liabilities 2,572 0 1,544 0
Total other income (expense) 2,581 1 1,316 4
Net income (loss) 513 (662) (11,105) (4,127)
Net income (loss) attributable to non-controlling interests (13) 0 (88) 0
Net income (loss) attributable to common stockholders $ 526 $ (662) $ (11,017) $ (4,127)
Net income (loss) per common share attributable to common stockholders:        
Basic (in dollars per share) $ 0.06 $ (0.45) $ (1.54) $ (2.86)
Diluted (in dollars per share) $ 0.06 $ (0.45) $ (1.54) $ (2.86)
Basic (in shares) 8,114,155 1,465,691 7,155,050 1,441,542
Diluted (in shares) 8,200,069 1,465,691 7,155,050 1,441,542